Scientific Program
(as per December 11th, 2018)
WEDNESDAY, DECEMBER 12, 2018 |
14.00 | Registration opens |
Opening | Session chairs afternoon: Emma Guttman (New York, USA) Patrick M. Brunner (Vienna, Austria) |
16.00 – 16.10 | Welcome address |
16.10 – 16.35 | Setting the stage – Historic perspectives Georg Stingl (Vienna, Austria) |
16.35 – 17.00 | Setting the stage – The translational revolution in inflammatory skin diseases James G. Krueger (New York, NY, USA) |
17.00 –17.30 | Two sides of Th17 cells in autoimmunity and tissue homeostasis Vijay Kuchroo (Boston, MA, USA) |
Session chairs evening: |
|
17.30 – 18.30 |
Oral presentations from selected abstracts #125 Selective oral JAK3 and TYK2/JAK1 kinase inhibitors both
#LB4 Guselkumab demonstrates superior long-term responses to secukinumab at Week48 in the treatment of moderate to severe psoriasis: Results from the ECLIPSE trial |
18.30 – 21.00 | Poster viewing and networking |
THURSDAY, DECEMBER 13, 2018 |
Session chairs morning: Sylvia Knapp (Vienna, Austria) Michael Detmar (Zurich, Switzerland) |
|
08.30 – 9.00 | A perspective of dendritic cells in inflammatory skin diseases Thomas Bieber (Bonn, Germany) |
09.00 – 09.30 | Resident T cells in health and disease Rachael Clark (Boston, MA, USA) |
09.30 – 10.00 | T cell subsets across inflammation and cancer Thomas S. Kupper (Boston, MA, USA) |
10.00 – 10.30 | Innate lymphoid cells in health and disease Graham Ogg (Oxford, United Kingdom) |
10.30 – 10.45 | Oral presentations from selected abstracts
#112 Resident T cells trigger disease-associated tissue responses that stratify clinical outcome in human psoriasis. |
10.45 – 11.00 | BREAK |
11.00 – 12.30 | Does Psoriasis Treatment Alter the Risk of Comorbidities? Examining the Evidence Symposium supported by Eli Lilly Chair: Kilian Eyerich (Munich, Germany)Psoriasis and Comorbidities: An Overview Kilian Eyerich (Munich, Germany) The Role of Cytokines in the Pathogenesis of Psoriasis and Associated Comorbidities Does Psoriasis Treatment affect Cardiovascular Disease? Psoriasis and Psyche: What Do We Know? Panel Discussion and Audience Q&A: Implications for Psoriasis Management Concluding Remarks and Close |
12.30 – 13.00 | BREAK |
Session chairs afternoon: |
|
13.00 – 14.00 |
Oral presentations from selected abstracts #138 Blood endotyping distinguishes the profile of vitiligo from other #102 Low-input RNA sequencing reveals survival program of human skin-resident T cells during complete myeloablation. #78 A critical role for IL-37 in regulatory T cell maintenance and CD4+ T cell inhibition. #70 KLK6-PAR1 signaling drives psoriasiform manifestations in skin and bone and blockade of PAR1 in explanted psoriasis patient skin decreases key psoriasis transcripts. |
14.00 – 14.30 | Protective immunity and immunodeficiencies Jean-Laurent Casanova (New York, NY, USA) |
14.30 – 15.30 | COFFEE BREAK |
Session chairs late afternoon: |
|
15.30 – 16.00 | Janus kinases in inflammation Massimo Gadina (Bethesda, MD, USA) on behalf of John O’Shea (Bethesda, MD, USA) |
16.00 – 16.30 | Visualization of skin inflammation and resulting immunologic concepts Kenji Kabashima (Kyoto, Japan) |
16.30– 17.00 | The microbiome and therapeutic implications Richard Gallo (San Diego, CA, USA) |
17.00-17.30 |
Oral presentations from selected abstracts #74 Triple correlation between skin microbiome, skin barrier and immune gene expression pathways in atopic dermatitis. #45 Baseline inflammatory biomarker profiles and clinical heterogeneity of adult patients with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids. |
Official Networking Evening |
FRIDAY, DECEMBER 14, 2018 |
08.00 – 09.30 | Discover the potential: exploring new frontiers of IL-23 inhibitors Symposium supported by Janssen Chair: Antonio Costanzo (Milano, Italy) & Kilian Eyerich (Munich, Germany) Welcome and introduction Advancing the science of psoriasis: the underlying pathology and the role IL-23 New horizons in managing psoriasis: individualizing care one patient at a time Interactive Q&A session Summary and closing |
09.30 – 09.45 | BREAK |
Session chairs morning: Stephan Weidinger (Kiel, Germany) James T. Elder (Ann Arbor, Michigan) |
|
09.45 – 10.15 | How to perform successful clinical trials in inflammatory skin diseases Kristian Reich (Hamburg, Germany) |
10.15 – 10.45 | Framing psoriasis James G. Krueger (New York, NY, USA) |
10.45 – 11.15 | Autoantigens in psoriasis Michel Gilliet (Lausanne, Switzerland) |
11.15 – 11.45 | Impact of immune targeted therapy on cardiovascular risk: The psoriasis model Joel Gelfand (Philadelphia, PA, USA) |
11.45 – 12.00 | BREAK |
12.00 – 13.30 | THE GREAT DEBATE: Should the Treatment Paradigm for Mild to Moderate Atopic Dermatitis (AD) Evolve? Symposium supported by Pfizer Moderator: Charles Lynde (Ontario, Canada) Invited Speaker: Aviv Barzilai (Tel Aviv, Israel) Invited Speaker: Adelaide A. Hebert (Houston,TX, USA) Invited Speaker: Torsten Zuberbier (Berlin, Germany) |
13.30 – 13.45 | BREAK |
Session chairs afternoon: Matthias Schmuth (Innsbruck, Austria) Zuhair Ballas (Iowa City, USA) |
|
13.45 – 14.15 | Inflammatory profile of atopic dermatitis and cytokine targeted treatments Emma Guttman (New York, NY, USA) |
14.15 – 14.45 | Barrier defects in atopic dermatitis and prevention strategies Alan Irvine (Dublin, Ireland) |
14.45 – 15.15 | Atopic dermatitis at disease onset Patrick M. Brunner (Vienna, Austria) |
15.15 – 15.45 | Adopting Orphan Ichthyoses: New Focus for Inflammatory Skin Research Amy S. Paller (Chicago, IL, USA) |
15.45 – 16.15 | COFFEE BREAK |
Session chairs late afternoon: Alain Hovnanian (Paris, France) Tove Agner (Copenhagen, Denmark) |
|
16.15 – 16.45 | Epicutaneous antigen desensitization Christophe Dupont (Paris, France) |
16.45 –17.15 | Peripheral tolerance to autoimmune target in pemphigus Masayuki Amagai (Tokyo, Japan) |
17.15-18.05 |
Oral presentations from selected abstracts #48 Conjunctival inflammation and loss of goblet cells in atopic dermatitis patients treated with dupilumab in daily practice.
#21 Sodium chloride is an ionic checkpoint for human Th2 cell responses and shapes the atopic skin micro environment |
SATURDAY, DECEMBER 15, 2018 |
08.00 – 09.30 | Atopic Dermatitis and Beyond: Pathogenic and Therapeutic Advances Symposium supported by Sanofi Genzyme Introduction Atopic Dermatitis: Emerging as a cytokine-driven disease and novel therapeutic developments Pediatric atopic dermatitis–pathogenic and therapeutic advances and implications for the atopic march Th2 Inhibition beyond atopic dermatitis Panel Discussion |
09.30 – 09.45 | BREAK |
Session chairs morning: |
|
09.45 – 10.00 | Oral presentations from selected abstracts
#120 Massive expansion of drug-specific, clonotypic and polycytotoxic CD8+ T cells in Toxic Epidermal Necrolysis. |
10.00 – 10.30 | Alopecia areata Ralf Paus (Manchester, UK) |
10.30 – 11.00 | Acne & Rosacea Martin Steinhoff (Dublin, Ireland) |
11.00 – 11.30 | Vitiligo John Harris (Worchester, MA, USA) |
11.30 – 12.00 | COFFEE BREAK |
Session chairs afternoon: Peter Wolf (Graz, Austria) Daniel Aletaha (Vienna, Austria) |
|
12.00 – 12.30 | Eosinophilic disorders Bruce Bochner (Chicago, IL, USA) |
12.30 – 13.00 | Adding new pieces to the old Lupus puzzle Virginia Pascual (New York, NY, USA) |
13.00 – 13.30 | Dermatomyositis: Pearls, Pitfalls, and an Evolving Therapeutic Landscape Ruth Ann Vleugels (Boston, MA, USA) |
Session chairs late afternoon: |
|
13.30 – 14.20 |
Oral presentations from selected abstracts #117 Early Improvement in Pruritus and Reduction in Clinical Signs in a Phase 2a Mechanism of Action Study of Crisaborole in Mild to Moderate Atopic Dermatitis.
|
14.20 – 14.30 | Closing session |